Jeffrey Testani, MD, MTR

Associate Professor Term

Departments & Organizations

Internal Medicine: Heart Failure Program

Yale Medicine

Office of Cooperative Research


Over the last decade, the study of cardio-renal interactions has enjoyed significant progress in the areas of basic science and epidemiology. From an epidemiologic standpoint, it has now been well documented that renal dysfunction in the setting of heart failure is tremendously common and one of the, if perhaps not the, most potent prognostic factors. Moreover, laboratory based research has yielded several novel therapeutic agents such as the adenosine antagonists, synthetic natriuretic peptides, and vasopressin antagonists. However, a limited understanding of the mechanistic basis for and specific phenotypes of cardio-renal dysfunction in humans has prevented targeted application of these “cardio-renal” therapies. As a result, translation of these novel therapies from bench to bedside has failed secondary to indiscriminant application in unselected heart failure populations.

The disappointing performance of these therapeutic approaches in clinical trials highlights the importance of bridging the large gap in knowledge between epidemiology and laboratory based research in this area. However, mechanistic study of this syndrome has proven complex due to the multiple different phenotypes of renal dysfunction that coexist (i.e., heart failure induced renal dysfunction, chronic kidney disease, treatment induced acute kidney injury) and the lack of a “gold standard” to differentiate these entities.

As such, the primary goals of my research program have been/are to: 1) provide proof of concept that mechanistically and prognostically distinct phenotypes of renal dysfunction in heart failure exist; 2) phenotype these candidate mechanistic subtypes in detail with respect to the operative renal and cardiac pathophysiology; 3) develop methodology to allow more accurate identification of mechanistic subtypes of renal dysfunction on the individual patient level; and 4) initiate trials of therapeutic strategies tailored to specific mechanistic phenotypes of cardio-renal dysfunction.

Education & Training

MS University of Pennsylvania Medical School (2012)
MD University of Florida (2004)
Fellowship Hospital of the University of Pennsylvania
Fellowship Hospital of the University of Pennsylvania
Residency Hospital of the University of Pennsylvania
Internship Hospital of the University of Pennsylvania
Board Certification AB of Internal Medicine, Cardiovascular Disease (2011)

Edit this profile

Contact Info

Jeffrey Testani, MD, MTR
Patient Care Locations
Yale CardiologyYale Physicians Building
800 Howard Avenue, Fl 2nd

New Haven, CT 06519
View on map...
Yale Cardiology175 Sherman Avenue, Ste 2nd Floor
New Haven, CT 06511
View on map...
Mailing Address
Cardiovascular MedicinePO Box 208017
New Haven, CT 06520